Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Amandeep SalhotraAhmed AribiDat NgoJianying ZhangKaramjeet SandhuMonzr Al-MalkiHaris AliPaul B KollerShukaib ArslanElizabeth BuddeSamer KhaledSanjeet DadwalDavid S SnyderAndrew ArtzStephen FormanRyotaro NakamuraAnthony SteinGuido MarcucciIbrahim AldossVinod A PullarkatPublished in: American journal of hematology (2021)